European office established, Appointment of EU Sales Manager and value-added reseller agreements with leading MS manufacturers in response to increased demand for RapidFire® mass spectrometry across Europe

WOBURN, Mass.–BIOCIUS Life Sciences Inc., developers of the label-free RapidFire® high-throughput mass spectrometry platform, today announced that it has expanded its operations, opening a European office and naming Gregory Werner as EU Sales Manager. Announcement of the new facility follows two other recent expansion activities: Announcement of Wako Pure Chemicals as Japanese distributor and of plans to move to a new, capacity-doubling headquarters in June.

“Since installation of our first European RapidFire system in July 2009, BIOCIUS has grown exponentially in Europe with additional systems throughout Germany, the UK, Sweden, Austria and Switzerland”

Located near Geneva, Switzerland, the new BIOCIUS subsidiary will provide expert sales and service support to the company’s growing European customer base. RapidFire technology enables pharmaceutical and biotechnology companies to accelerate their drug discovery research with high-throughput screening solutions for lead discovery and in vitro ADME applications.

“Since installation of our first European RapidFire system in July 2009, BIOCIUS has grown exponentially in Europe with additional systems throughout Germany, the UK, Sweden, Austria and Switzerland,” said Can ‘Jon’ Özbal, BIOCIUS’s COO. “This new office and experienced biotech professionals like Gregory will enable us to better focus on the needs of our European clients and continue to build that user base.”

BIOCIUS also extended its value-added reseller agreements with ABSciex and Agilent Technologies to include Europe, enabling BIOCIUS to offer an end-to-end high-throughput solution for drug discovery and analysis. “Expansion of our strategic relationships with mass spec market leaders ABSciex and Agilent allows us to provide our customers with a complete system – including a RapidFire integrated with either a triple-quadrupole or time-of-flight mass spectrometer,” said Jeffrey Leathe, Chairman and CEO of BIOCIUS. “Further strengthening these key collaborations combined with the addition of dedicated resources will enable us to build on RapidFire’s success in Europe and continue the growth trajectory BIOCIUS is currently experiencing.”

About BIOCIUS Life Sciences, Inc.

Named from the Greek word “BIO” (life) and the Latin word “OCIUS” (faster), BIOCIUS Life Sciences, provides the biopharmaceutical industry with faster answers: Products and services committed to speed and accuracy in drug discovery. Used by 13 of the top 15 pharmaceutical companies, BIOCIUS’s products and contract research services enable our partners to exceed their business goals.